keyword
MENU ▼
Read by QxMD icon Read
search

Vincent Rajkumar

keyword
https://www.readbyqxmd.com/read/30522590/current-emerging-and-anticipated-therapies-for-sickle-cell-disease
#1
EDITORIAL
Karl A Nath, S Vincent Rajkumar
No abstract text is available yet for this article.
December 2018: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/30516847/peripheral-blood-biomarkers-of-early-immune-reconstitution-in-newly-diagnosed-multiple-myeloma
#2
Moritz Binder, S Vincent Rajkumar, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Angela Dispenzieri, Lisa Hwa, Amie Fonder, Miriam Hobbs, Suzanne R Hayman, Steven R Zeldenrust, John A Lust, Stephen J Russell, Nelson Leung, Prashant Kapoor, Ronald S Go, Wilson I Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Robert A Kyle, Shaji K Kumar
Peripheral blood biomarkers of tumor microenvironment and immune surveillance are independent prognostic factors in multiple myeloma. The timing and prognostic impact of immune reconstitution has been studied after autologous hematopoietic stem cell transplantation, less is known about its significance in newly diagnosed multiple myeloma. We studied absolute lymphocyte (ALC) and monocyte (AMC) counts at the time of treatment initiation and one month thereafter in 771 newly diagnosed patients. Two hundred and thirty-four patients (31%) had evidence of immune dysregulation at baseline (abnormal biomarkers)...
December 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30510265/the-evaluation-of-monoclonal-gammopathy-of-renal-significance-a-consensus-report-of-the-international-kidney-and-monoclonal-gammopathy-research-group
#3
REVIEW
Nelson Leung, Frank Bridoux, Vecihi Batuman, Aristeidis Chaidos, Paul Cockwell, Vivette D D'Agati, Angela Dispenzieri, Fernando C Fervenza, Jean-Paul Fermand, Simon Gibbs, Julian D Gillmore, Guillermo A Herrera, Arnaud Jaccard, Dragan Jevremovic, Efstathios Kastritis, Vishal Kukreti, Robert A Kyle, Helen J Lachmann, Christopher P Larsen, Heinz Ludwig, Glen S Markowitz, Giampaolo Merlini, Peter Mollee, Maria M Picken, Vincent S Rajkumar, Virginie Royal, Paul W Sanders, Sanjeev Sethi, Christopher P Venner, Peter M Voorhees, Ashutosh D Wechalekar, Brendan M Weiss, Samih H Nasr
The term monoclonal gammopathy of renal significance (MGRS) was introduced by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The IKMG met in April 2017 to refine the definition of MGRS and to update the diagnostic criteria for MGRS-related diseases. Accordingly, in this Expert Consensus Document, the IKMG redefines MGRS as a clonal proliferative disorder that produces a nephrotoxic monoclonal immunoglobulin and does not meet previously defined haematological criteria for treatment of a specific malignancy...
December 3, 2018: Nature Reviews. Nephrology
https://www.readbyqxmd.com/read/30510245/microbiota-driven-interleukin-17-producing-cells-and-eosinophils-synergize-to-accelerate-multiple-myeloma-progression
#4
Arianna Calcinotto, Arianna Brevi, Marta Chesi, Roberto Ferrarese, Laura Garcia Perez, Matteo Grioni, Shaji Kumar, Victoria M Garbitt, Meaghen E Sharik, Kimberly J Henderson, Giovanni Tonon, Michio Tomura, Yoshihiro Miwa, Enric Esplugues, Richard A Flavell, Samuel Huber, Filippo Canducci, Vincent S Rajkumar, P Leif Bergsagel, Matteo Bellone
The gut microbiota has been causally linked to cancer, yet how intestinal microbes influence progression of extramucosal tumors is poorly understood. Here we provide evidence implying that Prevotella heparinolytica promotes the differentiation of Th17 cells colonizing the gut and migrating to the bone marrow (BM) of transgenic Vk*MYC mice, where they favor progression of multiple myeloma (MM). Lack of IL-17 in Vk*MYC mice, or disturbance of their microbiome delayed MM appearance. Similarly, in smoldering MM patients, higher levels of BM IL-17 predicted faster disease progression...
December 3, 2018: Nature Communications
https://www.readbyqxmd.com/read/30470751/clinical-predictors-of-long-term-survival-in-newly-diagnosed-transplant-eligible-multiple-myeloma-an-imwg-research-project
#5
Saad Z Usmani, Antje Hoering, Michele Cavo, Jesus San Miguel, Hartmut Goldschimdt, Roman Hajek, Ingemar Turesson, Juan Jose Lahuerta, Michel Attal, Bart Barlogie, Jae Hoon Lee, Shaji Kumar, Stig Lenhoff, Gareth Morgan, S Vincent Rajkumar, Brian G M Durie, Philippe Moreau
PURPOSE: multiple myeloma is considered an incurable hematologic cancer but a subset of patients can achieve long-term remissions and survival. The present study examines the clinical features of long-term survival as it correlates to depth of disease response. PATIENTS & METHODS: this was a multi-institutional, international, retrospective analysis of high-dose melphalan-autologous stem cell transplant (HDM-ASCT) eligible MM patients included in clinical trials...
November 23, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30463914/plasma-cell-proliferative-index-is-an-independent-predictor-of-progression-in-smoldering-multiple-myeloma
#6
Mohammed A Aljama, M Hasib Sidiqi, Arjun Lakshman, Angela Dispenzieri, Dragan Jevremovic, Morie A Gertz, Martha Q Lacy, Francis K Buadi, David Dingli, Eli Muchtar, Amie L Fonder, Suzanne R Hayman, Miriam A Hobbs, Wilson I Gonsalves, Rahma Warsame, Taxiarchis V Kourelis, Yi Lisa Hwa, Prashant Kapoor, Nelson Leung, Ronald S Go, Robert A Kyle, S Vincent Rajkumar, Shaji K Kumar
The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (>0.5). An elevated PCPI predicted an inferior time to progression (median, 3...
November 27, 2018: Blood Advances
https://www.readbyqxmd.com/read/30442928/revised-diagnostic-criteria-for-plasma-cell-leukemia-results-of-a-mayo-clinic-study-with-comparison-of-outcomes-to-multiple-myeloma
#7
Praful Ravi, Shaji K Kumar, Lindsey Roeker, Wilson Gonsalves, Francis Buadi, Martha Q Lacy, Ronald S Go, Angela Dispenzieri, Prashant Kapoor, John A Lust, David Dingli, Yi Lin, Stephen J Russell, Nelson Leung, Morie A Gertz, Robert A Kyle, P Leif Bergsagel, S Vincent Rajkumar
The current definition of plasma cell leukemia (PCL)- ≥ 20% circulating plasma cells (CPCs) on peripheral smear and plasma cell count ≥ 2 × 109 /L-may be too stringent. We reviewed outcomes of 176 multiple myeloma (MM) patients diagnosed between 1971 and 2016, and who had CPCs detectable at diagnosis, to determine whether a lower threshold could be used to diagnose PCL. Median overall survival (mOS) was 1.1 years (95% CI 0.8-1.4) and was similar between patients with < 5% (n = 54, mOS = 1...
November 15, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30409963/bortezomib-lenalidomide-and-dexamethasone-vrd-followed-by-autologous-stem-cell-transplant-for-multiple-myeloma
#8
M Hasib Sidiqi, Mohammed A Aljama, Irbaz Bin Riaz, Angela Dispenzieri, Eli Muchtar, Francis K Buadi, Rahma Warsame, Martha Q Lacy, David Dingli, Nelson Leung, Wilson I Gonsalves, Prashant Kapoor, Taxiarchis V Kourelis, William J Hogan, S Vincent Rajkumar, Shaji K Kumar, Morie A Gertz
We retrospectively reviewed all patients (n = 243) receiving bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by autologous stem cell transplantation (ASCT) for multiple myeloma at the Mayo Clinic between January 2010 and April of 2017. Median age was 61 (interquartile range, 55-67) with 62% of patients being male. High-risk cytogenetic abnormalities (HRA) were present in 34% of patients. A total of 166 (68%) patients received some form of maintenance/other therapy post transplant (no maintenance (NM, n = 77), lenalidomide maintenance (LM, n = 108), bortezomib maintenance (BM, n = 39), and other therapy (OT, n = 19))...
November 8, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30349651/aurora-kinase-and-fgfr3-inhibition-results-in-significant-apoptosis-in-molecular-subgroups-of-multiple-myeloma
#9
Utkarsh Painuly, Vijay Ramakrishnan, Teresa Kimlinger, Linda Wellik, Jessica Haug, Wilson Gonsalves, Lintao Bi, Zhongxia Huang, S Vincent Rajkumar, Shaji Kumar
Aberrant expression of proteins involved in cell division is a constant feature in multiple myeloma (MM), especially in high-risk disease. Increasingly, therapy of myeloma is moving towards individualization based on underlying genetic abnormalities. Aurora kinases are important mediators of cell cycle and are up regulated in MM. Functional loss of Aurora kinases results in genetic instability and dysregulated division leading to cellular aneuploidy and growth arrest. We investigated the role of Aurora kinase inhibition in MM, using a small molecule inhibitor A1014907...
October 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/30323358/relapse-after-complete-response-in-newly-diagnosed-multiple-myeloma-implications-of-duration-of-response-and-patterns-of-relapse
#10
Surbhi Sidana, Nidhi Tandon, Angela Dispenzieri, Morie A Gertz, Francis K Buadi, Martha Q Lacy, David Dingli, Amie L Fonder, Suzanne R Hayman, Miriam A Hobbs, Wilson I Gonsalves, Rahma M Warsame, Taxiarchis Kourelis, Yi Lisa Hwa, Prashant Kapoor, Robert A Kyle, Nelson Leung, Ronald S Go, S Vincent Rajkumar, Shaji K Kumar
Achieving a complete response (CR) is associated with improved overall survival (OS) in multiple myeloma (MM), but data on duration of CR (DurCR) are limited. We evaluated 351 patients (2004-2016), achieving CR with first-line therapy. Patients with sustained DurCR ≥ 24 months (n = 177) had better OS; 150 vs. 81 months, p < 0.001. DurCR ≥ 24 months remained a significant predictor for OS (HR: 0.3, 95% CI: 0.2-0.5, p < 0.001) after adjusting for age, revised ISS stage, transplant and maintenance therapy...
October 15, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315235/primary-systemic-amyloidosis-in-patients-with-waldenstr%C3%A3-m-macroglobulinemia
#11
Saurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, Morie A Gertz, Angela Dispenzieri, Eli Muchtar, Surbhi Sidana, Nidhi Tandon, S Vincent Rajkumar, David Dingli, Ronald Go, Martha Q Lacy, Taxiarchis Kourelis, Thomas E Witzig, David Inwards, Francis Buadi, Wilson Gonsalves, Thomas Habermann, Patrick Johnston, Grzegorz Nowakowski, Robert A Kyle, Shaji Kumar, Prashant Kapoor
No abstract text is available yet for this article.
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30305608/differences-in-genomic-abnormalities-among-african-individuals-with-monoclonal-gammopathies-using-calculated-ancestry
#12
Linda B Baughn, Kathryn Pearce, Dirk Larson, Mei-Yin Polley, Eran Elhaik, Michael Baird, Colin Colby, Joanne Benson, Zhuo Li, Yan Asmann, Terry Therneau, James R Cerhan, Celine M Vachon, A Keith Stewart, P Leif Bergsagel, Angela Dispenzieri, Shaji Kumar, S Vincent Rajkumar
Multiple myeloma (MM) is two- to three-fold more common in African Americans (AAs) compared to European Americans (EAs). This striking disparity, one of the highest of any cancer, may be due to underlying genetic predisposition between these groups. There are multiple unique cytogenetic subtypes of MM, and it is likely that the disparity is associated with only certain subtypes. Previous efforts to understand this disparity have relied on self-reported race rather than genetic ancestry, which may result in bias...
October 10, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30287814/recommendations-for-acquisition-interpretation-and-reporting-of-whole-body-low-dose-ct-in-patients-with-multiple-myeloma-and-other-plasma-cell-disorders-a-report-of-the-imwg-bone-working-group
#13
Lia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, Elena Zamagni, Jesus D Aquerreta, Charles L Roche, Suzanne Lentzsch, Philippe Moreau, Michele Cavo, Jesus San Miguel, Meletios A Dimopoulos, S Vincent Rajkumar, Brian G M Durie, Evangelos Terpos, Stefan Delorme
Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders...
October 4, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30267007/daratumumab-based-therapy-in-patients-with-heavily-pretreated-al-amyloidosis
#14
Jithma P Abeykoon, Saurabh Zanwar, Angela Dispenzieri, Morie A Gertz, Nelson Leung, Taxiarchis Kourelis, Wilson Gonsalves, Eli Muchtar, David Dingli, Martha Q Lacy, Suzanne R Hayman, Francis Buadi, Rahma Warsame, Robert A Kyle, Vincent Rajkumar, Shaji Kumar, Prashant Kapoor
No abstract text is available yet for this article.
September 28, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30258095/optimizing-deep-response-assessment-for-al-amyloidosis-using-involved-free-light-chain-level-at-end-of-therapy-failure-of-the-serum-free-light-chain-ratio
#15
Eli Muchtar, Angela Dispenzieri, Nelson Leung, Martha Q Lacy, Francis K Buadi, David Dingli, Suzanne R Hayman, Prashant Kapoor, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Wilson Gonsalves, Taxiarchis V Kourelis, Rahma Warsame, Stephen J Russell, John A Lust, Yi Lin, Ronald S Go, Steven R Zeldenrust, Robert A Kyle, S Vincent Rajkumar, Shaji K Kumar, Morie A Gertz
No abstract text is available yet for this article.
September 26, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30231405/value-and-cost-of-myeloma-therapy
#16
REVIEW
S Vincent Rajkumar
Major advances have occurred in the treatment of multiple myeloma, including several new drugs that typically cost more than $100,000 per year. Although the gains in myeloma therapy improve overall survival considerably, they are available to only a fraction of the population of patients with myeloma in the world because of regulatory barriers and cost. Myeloma is an example of what is happening in cancer on a much larger scale. Many of the problems discussed call for a wider discussion across all cancers, but they are amplified in myeloma because of the need for multidrug regimens that combine three or more expensive new drugs for prolonged periods of time...
May 23, 2018: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/30194770/utility-and-prognostic-value-of-18-f-fdg-positron-emission-tomography-computed-tomography-scans-in-patients-with-newly-diagnosed-multiple-myeloma
#17
Mohammed A Aljama, M Hasib Sidiqi, Francis K Buadi, Martha Q Lacy, Morie A Gertz, Angela Dispenzieri, David Dingli, Eli Muchtar, Amie L Fonder, Suzanne R Hayman, Miriam A Hobbs, Wilson I Gonsalves, Rahma M Warsame, Taxiarchis Kourelis, Yi Lisa Hwa, Prashant Kapoor, Robert A Kyle, Nelson Leung, Ronald S Go, S Vincent Rajkumar, Shaji K Kumar
Positron emission tomography-computed tomography (PET-CT) can identify bony lesions, assess disease burden, and detect extramedullary disease (EMD) in patients with multiple myeloma. We retrospectively reviewed records of patients who underwent PET-CT within 60 days of a new diagnosis (before therapy commenced) to identify the nature and prognostic impact of PET-CT abnormalities. Patients (N = 313) were seen from April 2005 through June 2017. Of the 234 patients (75%) with focal lesions (FLs), 182 (58%) had at least 3 FLs, 38 (12%) had EMD, and 204 (65%) had documented myelomatous lytic lesions...
December 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30190454/lenalidomide-and-dexamethasone-in-patients-with-relapsed-multiple-myeloma-and-impaired-renal-function-pre1003-a-precog-study
#18
Joseph Mikhael, Judith Manola, Amylou C Dueck, Suzanne Hayman, Kurt Oettel, Abraham S Kanate, Sagar Lonial, S Vincent Rajkumar
Renal insufficiency is common in patients with relapsed multiple myeloma and can often limit choice of therapy. Lenalidomide, a critical agent in the treatment of relapsed multiple myeloma, is renally cleared., This phase I/II trial evaluated the efficacy and safety of lenalidomide with dexamethasone in patients with relapsed multiple myeloma and renal insufficiency. Three groups were treated, with creatinine clearance 30-60 cc/hr (group A), CrCl < 30 not on dialysis (group B), and patients on dialysis (group C) at escalating doses of lenalidomide...
August 29, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30121949/predictors-of-symptomatic-hyperviscosity-in-waldenstr%C3%A3-m-macroglobulinemia
#19
Jithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, Jeffrey Winters, Morie A Gertz, Rebecca L King, David Murray, Thomas Habermann, David Dingli, Eli Muchtar, Ronald S Go, Nelson Leung, David J Inwards, Francis K Buadi, Angela Dispenzieri, Martha Q Lacy, Yi Lin, Wilson I Gonsalves, Taxiarchis Kourelis, Thomas E Witzig, Carrie Thompson, S Vincent Rajkumar, Robert A Kyle, Shaji Kumar, Prashant Kapoor
Symptomatic hyperviscosity is a well-established phenomenon in Waldenström macroglobulinemia (WM). Monoclonal IgM can variably impact intrinsic serum viscosity, leading to widely disparate symptomatic thresholds for development of hyperviscosity-related symptoms. Data regarding the predictors of symptomatic hyperviscosity and outcomes related to this complication remain scarce and a recent study proposed that IgM >6000 mg/dL be considered a new criterion for initiating therapy in otherwise asymptomatic (smoldering) WM to pre-empt hyperviscosity-related injury...
November 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30087461/plasma-cell-proliferative-index-post-transplant-is-a-powerful-predictor-of-prognosis-in-myeloma-patients-failing-to-achieve-a-complete-response
#20
M Hasib Sidiqi, Mohammed A Aljama, Dragan Jevremovic, William G Morice, Michael Timm, Francis K Buadi, Rahma Warsame, Martha Q Lacy, Angela Dispenzieri, David Dingli, Wilson I Gonsalves, Shaji Kumar, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, William J Hogan, Eli Muchtar, John A Lust, Vincent S Rajkumar, Morie A Gertz
Myeloma patients failing to achieve a complete response post autologous stem cell transplantation are heterogeneous, some ultimately achieving deeper responses and prolonged remission, whilst others relapse rapidly with poor outcomes. We evaluated the prognostic impact of the plasma cell proliferative index (PCPI) post-therapy, in 382 patients with myeloma failing to achieve complete response at 100 days post-transplant. Sixty percent (n = 230) of patients had zero clonal or too few clonal plasma cells to accurately assess PCPI (No PCPI)...
August 7, 2018: Bone Marrow Transplantation
keyword
keyword
168045
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"